Natus Medical Incorporated (BABY) Director William M. Moore Sells 5,000 Shares

Natus Medical Incorporated (NASDAQ:BABY) Director William M. Moore sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Natus Medical Incorporated (BABY) traded up $0.20 during trading hours on Friday, reaching $38.20. 698,960 shares of the company were exchanged, compared to its average volume of 393,447. The company has a market capitalization of $1,180.00, a PE ratio of 26.35 and a beta of 0.89. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. Natus Medical Incorporated has a fifty-two week low of $31.65 and a fifty-two week high of $43.85.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.02. The business had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The firm’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period last year, the firm posted $0.39 earnings per share. sell-side analysts predict that Natus Medical Incorporated will post 1.74 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/18/natus-medical-incorporated-baby-director-william-m-moore-sells-5000-shares.html.

Large investors have recently made changes to their positions in the stock. Eqis Capital Management Inc. increased its stake in Natus Medical by 25.0% in the third quarter. Eqis Capital Management Inc. now owns 16,740 shares of the medical equipment provider’s stock valued at $628,000 after acquiring an additional 3,353 shares during the last quarter. BlackRock Inc. boosted its position in Natus Medical by 137,510.8% in the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock valued at $161,874,000 after buying an additional 4,121,198 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Natus Medical by 9.7% in the second quarter. Bank of New York Mellon Corp now owns 973,346 shares of the medical equipment provider’s stock valued at $36,307,000 after buying an additional 86,192 shares in the last quarter. Virginia Retirement Systems ET AL boosted its position in Natus Medical by 122.3% in the second quarter. Virginia Retirement Systems ET AL now owns 26,900 shares of the medical equipment provider’s stock valued at $1,003,000 after buying an additional 14,800 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan boosted its position in Natus Medical by 3.2% in the second quarter. Municipal Employees Retirement System of Michigan now owns 7,760 shares of the medical equipment provider’s stock valued at $289,000 after buying an additional 240 shares in the last quarter. 99.53% of the stock is currently owned by institutional investors and hedge funds.

BABY has been the topic of several recent research reports. Zacks Investment Research cut shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. BidaskClub cut shares of Natus Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Natus Medical presently has a consensus rating of “Hold” and a consensus price target of $46.50.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply